Aim:
To investigate and validate the potential target proteins for drug repurposing of newly FDA approved antibacterial drug.
Background:
Drug repurposing is the process of assigning indications for drugs other than the one(s) that they were initially
developed for. Discovery of entirely new indications from already approved drugs is highly lucrative as it minimizes the
pipeline of the drug development process by reducing time and cost. In silico driven technologies made it possible to analyze molecules for different target proteins which are not yet explored.
Objective:
To analyze possible targets proteins for drug repurposing of lefamulin and their validation. Also, in silico prediction of novel scaffolds from lefamulin has been performed for assisting medicinal chemists in future drug design.
Methods:
A similarity-based prediction tool was employed for predicting target protein and further investigated using docking studies on PDB ID: 2V16. Besides, various in silico tools were employed for prediction of novel scaffolds from lefamulin using scaffold hopping technique followed by evaluation with various in silico parameters viz., ADME, synthetic accessibility and PAINS.
Results:
Based on the similarity and target prediction studies, renin is found as the most probable target protein for lefamulin. Further, validation studies using docking of lefamulin revealed the significant interactions of lefamulin with the binding
pocket of the target protein. Also, three novel scaffolds were predicted using scaffold hopping technique and found to be in
the limit to reduce the chances of drug failure in the physiological system during the last stage approval process.
Conclusion:
To encapsulate the future perspective, lefamulin may assist in the development of the renin inhibitors and, also
three possible novel scaffolds with good pharmacokinetic profile can be developed into both as renin inhibitors and for bacterial infections.
Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis